Conventional treatments for early stage PCa include watchful waiting (i.e., observation/no therapy), surgery and radiation, or active surveillance entailing routine monitoring of the blood level of prostate specific antigen (PSA), a circulatory biomarker for PCa cells, and repeat biopsy when deemed necessary. This evidence concerns the gene PROS1 and posterior cortical atrophy.